humulene and Epidermolysis-Bullosa

Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain care in EB; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been studied increasingly for pain conditions of various aetiologies and pose as a novel dimension for pain care in EB. We present three patients with EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol and cannabidiol. All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.

Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Cannabidiol; Cannabis; Dronabinol; Drug Combinations; Drug Therapy, Combination; Epidermolysis Bullosa; Female; Humans; Male; Middle Aged; Netherlands; Pain; Pain Measurement; Plant Oils; Treatment Outcome